δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders*

Background: Niemann-Pick disease type C and Wolman diseases are caused by mutations in genes responsible for intracellular cholesterol processing and trafficking. Results: δ-Tocopherol reduces lysosomal accumulation of cholesterol and other lipids potentially through enhancement of lysosomal exocytosis. Conclusion: δ-Tocopherol is a novel lead compound for drug development to treat lysosomal storage diseases. Significance: Lysosomal exocytosis may represent a new drug target broadly applicable to lysosomal storage diseases. Niemann-Pick disease type C (NPC) and Wolman disease are two members of a family of storage disorders caused by mutations of genes encoding lysosomal proteins. Deficiency in function of either the NPC1 or NPC2 protein in NPC disease or lysosomal acid lipase in Wolman disease results in defective cellular cholesterol trafficking. Lysosomal accumulation of cholesterol and enlarged lysosomes are shared phenotypic characteristics of both NPC and Wolman cells. Utilizing a phenotypic screen of an approved drug collection, we found that δ-tocopherol effectively reduced lysosomal cholesterol accumulation, decreased lysosomal volume, increased cholesterol efflux, and alleviated pathological phenotypes in both NPC1 and Wolman fibroblasts. Reduction of these abnormalities may be mediated by a δ-tocopherol-induced intracellular Ca2+ response and subsequent enhancement of lysosomal exocytosis. Consistent with a general mechanism for reduction of lysosomal lipid accumulation, we also found that δ-tocopherol reduces pathological phenotypes in patient fibroblasts from other lysosomal storage diseases, including NPC2, Batten (ceroid lipofuscinosis, neuronal 2, CLN2), Fabry, Farber, Niemann-Pick disease type A, Sanfilippo type B (mucopolysaccharidosis type IIIB, MPSIIIB), and Tay-Sachs. Our data suggest that regulated exocytosis may represent a potential therapeutic target for reduction of lysosomal storage in this class of diseases.

[1]  A. Galione,et al.  Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium , 2008, Nature Medicine.

[2]  D. Ory,et al.  Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression , 2009, PloS one.

[3]  H. Ninomiya,et al.  [Niemann-Pick disease type C]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[4]  K. Sandhoff,et al.  Lysosomal lipid storage diseases. , 2011, Cold Spring Harbor perspectives in biology.

[5]  J. Katsaras,et al.  The location and behavior of alpha-tocopherol in membranes. , 2010, Molecular nutrition & food research.

[6]  M. Patterson,et al.  PART 16 : LYSOSOMAL DISORDERS Chapter 145 : Niemann-Pick Disease Type C : A Lipid Trafficking Disorder , 2007 .

[7]  O. Qureshi,et al.  Regulation of P2X4 receptors by lysosomal targeting, glycan protection and exocytosis , 2007, Journal of Cell Science.

[8]  Joseph L. Goldstein,et al.  Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol , 2009, Cell.

[9]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[10]  S. Patel,et al.  Type C Niemann-Pick disease. Abnormal metabolism of low density lipoprotein in homozygous and heterozygous fibroblasts. , 1986, The Journal of biological chemistry.

[11]  R. Arantes,et al.  A Role for Synaptotagmin VII-Regulated Exocytosis of Lysosomes in Neurite Outgrowth from Primary Sympathetic Neurons , 2006, The Journal of Neuroscience.

[12]  Xianlin Han,et al.  Toward fingerprinting cellular lipidomes directly from biological samples by two-dimensional electrospray ionization mass spectrometry. , 2004, Analytical biochemistry.

[13]  R. Brady,et al.  Lysosomal Storage Diseases , 1986, The Lancet.

[14]  B. Davidson,et al.  Clarifying lysosomal storage diseases , 2011, Trends in Neurosciences.

[15]  S. Pfeffer,et al.  Niemann–Pick type C 1 function requires lumenal domain residues that mediate cholesterol-dependent NPC2 binding , 2011, Proceedings of the National Academy of Sciences.

[16]  P. Yancey,et al.  Importance of different pathways of cellular cholesterol efflux. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[17]  A. Ballabio,et al.  Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance , 2011, Developmental cell.

[18]  K. Nagashima,et al.  Biological tissue and cell culture specimen preparation for TEM nanoparticle characterization. , 2011, Methods in molecular biology.

[19]  L. Appel,et al.  Supplementation of Diets with α-Tocopherol Reduces Serum Concentrations of γ- and δ-Tocopherol in Humans , 2003 .

[20]  S. Lemaire-Ewing,et al.  7-Ketocholesterol Incorporation into Sphingolipid/Cholesterol-enriched (Lipid Raft) Domains Is Impaired by Vitamin E , 2009, The Journal of Biological Chemistry.

[21]  M. Pineda,et al.  New agents and approaches to treatment in Niemann-Pick type C disease. , 2011, Current pharmaceutical biotechnology.

[22]  Elina Ikonen,et al.  Cellular cholesterol trafficking and compartmentalization , 2008, Nature Reviews Molecular Cell Biology.

[23]  D. Sviridov,et al.  Asymmetry in the Lipid Affinity of Bihelical Amphipathic Peptides , 2008, Journal of Biological Chemistry.

[24]  C. Sen,et al.  Tocotrienols: Vitamin E beyond tocopherols. , 2006, Life sciences.

[25]  C. Cross,et al.  Dietary alpha-tocopherol and neuromuscular health: search for optimal dose and molecular mechanisms continues! , 2010, Molecular nutrition & food research.

[26]  N. Yoshida,et al.  Starvation and rapamycin differentially regulate host cell lysosome exocytosis and invasion by Trypanosoma cruzi metacyclic forms , 2011, Cellular microbiology.

[27]  T. Koeda,et al.  Type C Niemann-Pick disease Detection and quantification of cholesterol-accumulating cells in bone marrow , 1993, Brain and Development.

[28]  A. Norman,et al.  Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. , 1972, The Journal of biological chemistry.

[29]  Y. Ioannou,et al.  Cyclodextrin Induces Calcium-Dependent Lysosomal Exocytosis , 2010, PloS one.

[30]  R. Brigelius-Flohé,et al.  alpha-Tocopherol enhances degranulation in RBL-2H3 mast cells. , 2010, Molecular nutrition & food research.

[31]  C. Patterson,et al.  Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. , 2008, The American journal of clinical nutrition.

[32]  J. Breslow,et al.  Intracellular Cholesterol Transport , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[33]  D. Rader,et al.  Phenotypic correction of lipid storage and growth arrest in wolman disease fibroblasts by gene transfer of lysosomal acid lipase. , 2001, Human gene therapy.

[34]  Paul Helquist,et al.  Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts , 2011, Proceedings of the National Academy of Sciences.

[35]  W. Pavan,et al.  Plasma and Tissue Concentrations of α-Tocopherol and δ-Tocopherol Following High Dose Dietary Supplementation in Mice , 2012, Nutrients.

[36]  R. Parker,et al.  Influence of major structural features of tocopherols and tocotrienols on their ω-oxidation by tocopherol-ω-hydroxylase Published, JLR Papers in Press, February 6, 2007. , 2007, Journal of Lipid Research.

[37]  R. Parker,et al.  Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. , 2002, The Journal of biological chemistry.

[38]  M. Wolman.  Wolman Disease and Its Treatment , 1995, Clinical pediatrics.

[39]  S. Morley,et al.  The α‐Tocopherol Transfer Protein , 2007 .

[40]  H. Büssow,et al.  Exocytosis of storage material in a lysosomal disorder. , 2005, Biochemical and biophysical research communications.

[41]  F. Maxfield,et al.  Chemical screen to reduce sterol accumulation in Niemann-Pick C disease cells identifies novel lysosomal acid lipase inhibitors. , 2009, Biochimica et biophysica acta.

[42]  H. Du,et al.  42. Wolman disease/cholesteryl ester storage disease: Efficacy of plant-produced human lysosomal acid lipase in mice , 2009 .

[43]  E. Caler,et al.  Plasma Membrane Repair Is Mediated by Ca2+-Regulated Exocytosis of Lysosomes , 2001, Cell.

[44]  D. Ory.  The niemann-pick disease genes; regulators of cellular cholesterol homeostasis. , 2004, Trends in cardiovascular medicine.

[45]  E. Eggermont.  Recent advances in vitamin E metabolism and deficiency , 2006, European Journal of Pediatrics.

[46]  J. Alroy,et al.  Ultrastructural findings in skin from patients with Niemann-Pick disease, type C. , 1990, Pediatric neurology.

[47]  C. Cellai,et al.  Altered cholesterol ester cycle in skin fibroblasts from patients with Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[48]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[49]  R. Gillies,et al.  Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. , 2004, Journal of applied genetics.

[50]  J. Repa,et al.  Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1−/− mouse , 2009, Proceedings of the National Academy of Sciences.

[51]  Marie T. Vanier,et al.  Niemann–Pick disease type C , 2003, Clinical genetics.